• 에너지공학
• /
• 제23권2호
• /
• pp.49-56
• /
• 2014

생물학적 하수처리공정에서 안정적인 방류수질 확보와 처리 비용을 적게 하는 것은 매우 중요하다. 하지만 유입수 유량 및 성분 농도의 변화와 미생물의 비선형적인 동특성, 기타 환경 요인에 의해서 최적의 운전 제어를 하기가 쉽지 않기 때문에, 기존의 하수처리장에서는 필요한 양 이상의 폭기 및 화학물질을 과량 주입하는 방법 등을 사용하였다. 본 연구에서는 포기조에서 미생물에 필요한 용존산 소농도를 유지함과 동시에 과폭기로 인한 전력 비용을 감소할 수 있는 최적 제어 방법을 제안하였다. 최적 제어를 위하여 실시간 미생물 호흡률 측정기(Oxygen uptake rate, OUR)을 이용하여 측정하였고, 실시간 호흡률 측정값을 바탕으로 현재 미생물에 필요한 최적 DO 농도를 제안하였으며, 이에 따라 공기송풍기가 자동제어될 수 있도록 구성하였다. 최적 제어 방법을 통하여 하수처리장 포기조의 공기 송풍량에 소요되는 전력비용을 절감할 수 있었다.

• 대한환경공학회지
• /
• 제28권11호
• /
• pp.1141-1147
• /
• 2006

경제성을 고려한 새로운 PAC 선정방법을 적용하고자 상수원수 내 MIB와 유기물 제거를 위한 PAC 흡착실험을 수행하였다. PAC 투입량이 증가함에 따라 MIB 제거율은 증가하는 경향을 보였으며, 석탄계 PAC가 목탄계 PAC에 비해 MIB 제거율이 우수한 것으로 나타났다. DOC 및 $UV_{254}$의 제거율은 PAC와 원수 종류에 따라 큰 차이를 보이지는 않았으나, MIB 제거율에 비해 떨어지는 결과를 보였다. MIB, DOC, 그리고 $UV_{254}$ 제거율은 실험에 사용한 PAC들 중에서 P-1000 PAC가 가장 좋았다. EEM 결과에 의하면 모든 시료에 존재하는 대부분의 유기물은 Fulvic산과 유사한 물질인 것으로 판명되었다. 특히, PAC 접촉 이후 대상 시료에 존재하는 유기물 중에서 Fulvic산과 유사한 유기물, Humic과 유사한 유기물, 그리고 SMP와 유사한 유기물 등이 줄어드는 경향을 보였다. 경제성을 고려한 PAC 선정방법에 의해 MCI 값이 가장 낮은 P-1000이 가장 적합한 PAC로 선정되었다. 최종적으로 선정하기에 앞서 PAC의 효율성 및 취급용이성, PAC의 입자크기 및 분포, 그리고 DOC 농도에 따른 PAC 투입비용 등도 고려해야 할 것으로 판단된다.

• 분석과학
• /
• 제17권4호
• /
• pp.337-346
• /
• 2004

근육강화제의 일종인 7-keto-dehydroepiandrosterone-acetate (7-keto-DHEA-acetate)를 투여시킨 후 사람의 뇨를 통해서 배설되는 대사체들을 확인하고 그 결과를 향후 도핑 검사에 있어서 금지 약물로 선정될 경우를 대비한 기초 연구를 진행하고자 하였다. 먼저 뇨 시료의 매트릭스로부터 7-keto-DHEA-acetate가 방해 없이 효과적으로 검출되는 것을 알아보았으며, 약물을 복용한 dosed urine에 배설되는 대사체를 검출하기 위하여 LC/ESI/MS와 GC/MSD를 사용하였다. 그 결과 바탕 뇨 시료에서 나타나지 않은 여러 개의 새로운 화합물들이 복용 뇨 시료에서 검출되었으며 이들을 M1, M2, M3, M4 및 M5로 구별 하였으며 이 결과들로부터 대사체 M1과 M2는 물분자가 제거될 수 있는 히드록시기나 케톤기를 세 개 이상 가진 구조일 것으로 예상되었다. M1의 경우, m/z 518 이 분자이온이라면 분자량이 302인 이 대사체는 3번과 17번 탄소 위치에 케톤기, 7번 탄소위치에서 히드록시기를 가지는 구조인 7-OH-androstendione이라고 예상 할 수 있었으며, M2의 경우에는 M1 대사체와 마찬가지로 m/z 518이 분자이온이라면 분자량이 302인 이 대사체는 3번 탄소 위치에 히드록시기가 있고 17번 탄소 위치에 케톤기를 가지며 7번 탄소위치에 케톤기가 있는 구조인 7-keto-DHEA로 판단되었다.

• Journal of Preventive Medicine and Public Health
• /
• 제40권2호
• /
• pp.155-161
• /
• 2007

Objectives : Bisphenol A diglycidyl ether (BADGE) is the major component in commercial liquid epoxy resins, which are manufactured by co-reacting bisphenol A with epichlorohydrin. This study was performed to show the developmental effects of prenatal and postnatal exposures to BADGE in male rat offspring. Methods : Mated female rats were divided into four groups, each containing 12 rats. The dosing solutions were prepared by thoroughly mixing BADGE in corn oil at the 0, 375, 1500 and 3000 mg/kg/day concentrations. Mated females were dosed once daily by oral gavage on gestation day (GD) 6 - 20 and postnatal day (PND) 0 - 21. Pregnant female dams were observed general symptoms and body weight. Also, male pups were observed the general symptoms, body weight, developmental parameters (e.g. anogenital distance, pina detachment, incisor eruption, nipple retention, eye opening, testis descent), organ pathologic changes and hormone levels of plasma. Results : Pregnant rats treated with BADGE died at a rate of about 70% in the 1500 mg/kg/day group and all rats treated with 3000 mg/kg/day died. Body weight, for male pups treated with doses of 375 mg/kg/day, was significantly lower than in the control group at PND 42, 56, and 63 (p<0.05). Evaluation of body characteristics including; separation of auricle, eruption of incisor, separation of eyelid, nipple retention, descent of testis, and separation of the prepuce in the BADGE treated group showed no difference in comparisons with the control group. AGD and adjusted AGD (mm/kg) for general developmental items in BADGE 375 mg/kg/day treated pups tended to be longer than in controls, however, these differences were not statistically significant. Relative weights of adrenal gland, lung (p<0.05), brain, epididymis, prostate, and testis (p<0.01) were heavier than in control in measures at PND 9 weeks. There were no significant changes in comparisons of histological findings of these organs. Loss of spermatids was observed in the seminiferous tubule at PND 9 weeks, but no weight changes were observed. The plasma estrogen levels were similar in the control and treatment groups at PND 3, 6 and 9 weeks. The plasma testosterone levels in the control group tended to increase with age. However, in the BADGE 375 mg/kg/day treated male pups it did not tend to increase. Conclusions : These findings suggest that BADGE is a chemical that has developmental effects consistent with it being an endocrine disruptor.

• 한국임상약학회지
• /
• 제9권1호
• /
• pp.49-54
• /
• 1999

This study was carried out to compare the bioavailability of Hanmi clarithromycin (250 mg/tablet) with that of $Klaricid^{(R)}$ The bioavailability was examined on 20 volunteers who received a single dose (500 mg) of each drug in the fasting state in a randomized balanced 2-way crossover design. After dosing, blood samples were collected for a period of 12 hours. Plasma samples were analyzed for clarithromycin and roxithromycin(internal standard) by HPLC/Coulometric BCD. The pharmaco-kinetic parameters ($AUC_{0-l2hr}$, Cmax, Tmax, $AUC_{inf}$, Ka, Kel, $t_{1/2}$, Vd/F and Cl/F) were calculated from the plasma clarithromycin concentration-time data of each volunteer. The computer program 'WinNonlin' was used for compartmental analysis. One compartment model with first-order input, from order output with lag time, weighting factor $l/y^2$ was chosen as the appropriate pharmacokinetic model. The major pharmacokinetic parameters ($AUC_{0-l2hr},\;AUC_{inf}$, Cmax and Tmax) of Hanmi clarithromycin were $10.7\pm0.5\;{\mu}g{\cdot}hr{\cdot}ml^{-1},\;12.7\pm0.7\;{\mu}g{\cdot}hr{\cdot}ml^{-1},\;1.7\pm0.1\;{\mu}g/ml\;and\;2.0\pm0.2\;hr$, respectively, and those of $Klaricid^{(R)}\;were\;9.8\pm0.5\;{\mu}g{\cdot}hr{\cdot}ml^{-1},\;11.7\pm0.6\;{\mu}g{\cdot}hr{\cdot}ml^{-1},\;1.6\pm0.1\;{\mu}g/ml\;and\;2.1\pm0.1\;hr$, respectively. The differences in mean values of $AUC_{0-l2hr},\;AUC_{inf}$ and Cmax between two products were $9.88\%,\;8.94%\;and\;6.59\%$, respectively. The least significant differences at $\alpha=0.05$ for $AUC_{0-l2hr},\;AUC_{inf}$ and Cmax were $16.08\%,\;17.81\%\;and\;18.94\%$, respectively. Though the plasma clarithromycin concentrations of Hanmi clarithromycin were higher than those of $Klaricid^{(R)}$ at all observed times, the bioavailability of Hanmi clarithromycin appeared to be bioequivalent with that of $Klaricid^{(R)}$. The Ka, Kel, $t_{1/2}$, Vd/F and Cl/F of the Hanmi clarithromycin were $2.69\pm0.53\;hr^{-1},\;0.18\pm0.01 hr^{-1},\;3.9\;hr,\;248.8\pm11.4\;L\;and\;43.7\pm2.6\;L/hr$, respectively, and those of $Klaricid^{(R)} were 2.19\pm0.51\;hr^{-1},\;0.18\pm0.02\;hr^{-1},\;3.7\;hr,\;266.7\pm22.4\;L\;and\;45.3\pm2.8L/hr$, respectively. There were no statistically significant differences between two drugs in all pharmacokinetic parameters.

• 한국토양비료학회지
• /
• 제40권2호
• /
• pp.114-117
• /
• 2007

가축용 구충제로 사용되어지고 있는 ivermectin이 토양 동물중 대표적인 비표적 생물인 지렁이(Eisenia fetida)에 미치는 영향을 조사하였다. Ivermectin $250{\mu}g$를 피하주사한 소로부터 배출되는 우분을 1, 2, 3, 7일째 채취하여 생물검정을 시도한 결과 1, 2일째 배출된 우분은 급성 독성을 나타내어 73.7%와 98.3%의 치사율을 보였다. 또한 발육율에 있어서도 1일째 우분을 섭취한 줄지렁이의 발육이 대조군에 비해 현저히 떨어지는 것으로 나타났고, 전혀 산란을 하지 못했다. Ivermectin 처리후 1, 2 일째 배출된 우분은 지렁이에 있어 급성독성을 나타내고 2세대의 부화율에도 영향을 미치지만, 3일째 이후 배출된 우분에서는 급성 및 만성독성은 나타나지 않았다. 결과적으로, ivermectin을 소에 처리하고 1, 2일째 배설된 우분에는 상당량의 ivermectin이 함유되어 지렁이등과 같은 분해성 비표적 생물의 발육에 영향을 미칠 수 있음이 관찰되어 초지에서 영양물질 순환의 차원에서나 지렁이 먹이로써의 우분에 대한 관리가 요망되는 바이다.

• 한국임상약학회지
• /
• 제31권3호
• /
• pp.180-187
• /
• 2021

Objective: We investigated arthralgia and myalgia associated with the use of oral bisphosphonate (BP) by conducting a survey of patient. Methods: The pharmacists conducted a survey between 1 Oct 2019 and 30 Sep 2020 among patients who were dispensed BP in community pharmacies to assess their demographic and medical characteristics, and their experiences with, and process for pain. Logistic regression analyses were performed to find the risk factors associated with the pain, and the odds ratios (OR) and 95% confidence intervals (CI) were determined. Results: A total of 160 patients who used BP participated in the survey (74 [46.3%] used risedronate; 61 [38.1%] used alendronate; 23 [14.4%] used ibandronate), and 20 (12.5%) of them experienced pain. Significant statistical differences of the characteristics between patients who experienced pain or not were observed regarding menopause, and parity. Compared with women who had one or two parity, women who had more than three parity were associated with the decreased risk of pain (OR, 0.24; 95% CI, 0.04-0.98). Moreover, steady exercise was associated with the decreased risk of pain compared to less exercise (OR, 0.37; 95% CI, 0.14-0.98). Conclusion: Our findings suggest that the risk of pain in BP-treated patients might be different regarding the different ingredients of BP, and dosing frequency. This survey highlights a need for a further safety research to understand the factors influencing the pain associated with the BP treatment.

• 한방재활의학과학회지
• /
• 제31권4호
• /
• pp.157-166
• /
• 2021

Objectives This study is designed to evaluate the safety of Bojungikgi-tang soft extract in healthy male volunteers. Methods 12 healthy male volunteers were recruited and this study was carried out by a single center. Laboratory test results, vital signs of the volunteers were collected to evaluate safety. According to registration order, the 12 subjects were allocated by serial number. To evaluate safety, blood samples were taken and vital signs were checked 4 times - screening, pre administration, post administration and follow up-during the whole trial. The difference between pre (before medication [0 hr]) and post-administration (after medication [48 hr]) variables was summarized as mean±standard deviation. The normality test was performed using the Kolmogorov-Smirnov test and Shapiro-Wilk test. When the normality is satisfied, the paired t-test is applied. Otherwise, the non-parametric method, Wilcoxon signed rank test is applied. The significance level was p<0.05. The incidence of all adverse effects are shown in percentage. Results In the case of red blood cell, hemoglobin, hematocrit, lymphocytes, neutrophils, protein, γ-glutamyl transpeptidase values, the normality test result of the variable for the difference value before and after the dosing has a significance level <0.05. But most of values did not deviate from the normal range, and the deviation from the normal range could not be regarded as the significance associated with this clinical trial. And adverse event wasn't observed associated with the clinical trial drug. Conclusions Bojungikgi-tang soft extract were considered to be safe for healthy male volunteers.

• 대한방사선기술학회지:방사선기술과학
• /
• 제42권3호
• /
• pp.209-215
• /
• 2019

Comparison of the effective dose of the chest and the equivalent dose of the lens site in the radiation workers working at four medical institutions with the PET / CT room located in one metropolitan city and province from April 1 to June 30, 2018 Respectively. Radioactive medicine were measured at the time of dispensing and at the time of injection. In this experiment, the average dispensing time per patient was 5.7 minutes and the average injection time was 3.1 minutes. The equivalent dose at the lens site was $0.78{\mu}Sv/h$ for 1 mCi, and the effective dose for chest was $0.18{\mu}Sv/h$ per 1 mCi. The equivalent dose at the lens site during injection was $0.88{\mu}Sv/h$ per mCi and the effective dose of chest was $0.20{\mu}Sv/h$ per mCi. The daily effective dose of the chest was $0.9{\pm}0.6{\mu}Sv$ and the equivalent dose of the lens site was $3.6{\pm}1.4{\mu}Sv$ during daily dosing for 20 days. The effective dose of the chest during the day was $0.6{\pm}0.5{\mu}Sv$ and the equivalent dose of the lens was $2.2{\pm}1.0{\mu}Sv$. At the time of dispensing, the equivalent dose of the lens was $0.187{\pm}0.035mSv$, the effective dose of the chest was $0.137{\pm}0.055mSv$, the equivalent dose of the lens was $0.247{\pm}0.057mSv$, and the effective dose of the monthly chest was $0.187{\pm}0.021mSv$. As a result of the corresponding sample test, the equivalent dose and the effective dose of the chest, the effective dose of the chest, the effective dose of the chest, the effective dose of the chest, The equivalent dose of the lens and the effective dose of the chest were statistically significant (p<0.05) with a significance of 0.000. However, there was no statistically significant difference (p>0.05) between the equivalent dose and the effective dose of the chest, the equivalent dose of the lens at the time of injection, and the effective dose of the chest at 0.138 and 0.230, respectively.

• Translational and Clinical Pharmacology
• /
• 제26권4호
• /
• pp.160-165
• /
• 2018

Indobufen ($Ibustrin^{(R)}$), a reversible inhibitor of platelet aggregation, exists in two enantiomeric forms in 1:1 ratio. Here, we characterized the anti-platelet effect of S- and R-indobufen using response surface modeling using $NONMEM^{(R)}$ and predicted the therapeutic doses exerting the maximal efficacy of each enantioselective S- and R-indobufen formulation. S- and R-indobufen were added individually or together to 24 plasma samples from drug-naïve healthy subjects, generating 892 samples containing randomly selected concentrations of the drugs of 0-128 mg/L. Collagen-induced platelet aggregation in platelet-rich plasma was determined using a Chrono-log Lumi-Aggregometer. Inhibitory sigmoid $I_{max}$ model adequately described the anti-platelet effect. The S-form was more potent, whereas the R-form showed less inter-individual variation. No significant interaction was observed between the two enantiomers. The anti-platelet effect of multiple treatments with 200 mg indobufen twice daily doses was predicted in the simulation study, and the effect of S- or R-indobufen alone at various doses was predicted to define optimal dosing regimen for each enantiomer. Simulation study predicted that 200 mg twice daily administration of S-indobufen alone will produce more treatment effect than S-and R-mixture formulation. S-indobufen produced treatment effect at lower concentration than R-indobufen. However, inter-individual variation of the pharmacodynamic response was smaller in R-indobufen. The present study suggests the optimal doses of R-and S-enantioselective indobufen formulations in terms of treatment efficacy for patients with thromboembolic problems. The proposed methodology in this study can be applied to the develop novel enantio-selective drugs more efficiently.